


**May 2010**

Volume 15 · Numbers 9/10

pp. 325–408

**Cover Story**

The leading story of this issue of Drug Discovery Today, by Lijun Shi, Caiping Mao, Zhice Xu and Lubo Zhang, deals with the topic of "Angiotensin-converting enzymes and drug discovery in cardiovascular diseases". The value of the renin-angiotensin system is well-known and has been long-established. Pharmacologically, the system has occupied a pivotal position in the development of drugs for disorders of the cardiovascular system. Of the various players in the system, angiotensin-converting enzyme (ACE) has been shown to be a useful, druggable target for the treatment of cardiovascular disease. In this review, the authors cover the various metabolic pathways of ACE and ACE2 for their potential for novel drug development.

DRUG DISCOVERY TODAY

REVIEWS

KEYNOTE

332 Angiotensin-converting enzymes and drug discovery in cardiovascular diseases

Lijun Shi, Caiping Mao, Zhice Xu and Lubo Zhang

342 ATPase inhibitors of heat-shock protein 90, second season

Yves L. Janin

GENE TO SCREEN

354 New promising drug targets in cancer- and metastasis-initiating cells

Murielle Mimeault and Surinder K. Batra

INFORMATICS

365 Biochemical modeling with Systems Biology Graphical Notation

Andreas Jansson and Mats Jirstrand

POST SCREEN

371 Progress in corticotropin-releasing factor-1 antagonist development

Eric P. Zorrilla and George F. Koob

384 Impact of new technologies for cellular screening along the drug value chain

Clemens Möller and Mark Slack

391 The nasty surprise of a complex drug–drug interaction

Chris Bode

396 Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD

Jaymin B. Morjaria, Mario Malerba and Riccardo Polosa

DRUG DISCOVERY TODAY**Editorial****Editor:** Steve Carney**Assistant Editor:** Kirsty Strawbridge**Content Development Manager:** Joanna Aldred**Journal Manager:** Basil Nyaku**Publisher:** Jaap van Harten**Editorial Enquiries:***Drug Discovery Today*

Elsevier

32 Jamestown Road, London, NW1 7BY, UK

Tel: +44 (0)20 7424 4200

Fax: +44 (0)1865 853067

Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD**Jurgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Vertex Pharmaceuticals, USA***David Cavalla** *Arachnova, UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *Rosetta Genomics, USA***Donald Daley** *Argenta Discovery, UK***Sean Ekins** *ACT LLC and Collaborations in Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Organon, UK***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong, Hong Kong***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Meliior Discovery, USA***Lorenz Mayr** *Novartis, Switzerland***Nick Meanwell** *Bristol-Myers Squibb, USA***BK Muralidhara** *Pfizer Global Biologics, St. Louis, USA***Mark Murcko** *Vertex Pharmaceuticals, USA***Fajun Nan** *Shanghai Institute of Materia Medica, China***Pradeep Nathan** *Experimental Medicine, GSK and University of Cambridge***Gitte Neubauer** *Cellzome, Germany***Eric Neumann** *Teranode, USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Aurigene, USA***Manuel Peitsch** *Novartis, Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd. USA***Janice Reichert** *Tufts Center for the Study of Drug Development, USA***John Reidhaar-Olson** *Hoffmann-La Roche, USA***Mike Romanos** *GlaxoSmithKline, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Esther Schmid** *Pfizer, UK***Jonathan Sheldon** *Inforsense, UK***Michael Snyder** *Yale University, USA***Susie Stephens** *Eli Lilly and Co. Ltd., USA***Robert Strausberg** *The J. Craig Venter Institute, USA***Donny Strosberg** *Scripps Florida, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston, USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Johnson and Johnson, Belgium***Limsoon Wong** *Laboratories for Information Technology (LIT), Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical School, USA*

DRUG DISCOVERY TODAY

EDITORIAL

325 Pharmacogenetics—pivotal to the future of the biopharmaceutical industry

Elizabeth Foot, Dominique Kleyn and Emma Palmer Foster

PERSPECTIVE

FEATURE

328 Use of Benford's law in drug discovery data

Masaya Orita, Ayako Moritomo, Tatsuya Niimi and Kazuki Ohno

MONITOR

406 HCV protease inhibitor telaprevir: phase II clinical results

Kevin Peese

407 DIARY

FORTHCOMING ARTICLES:

New strategies to improve the intranasal absorption of insulin*By Xiaopin Duan and Shirui Mao***Combinatorial Domain Hunting: solving problems in protein expression***By Edward Littler***Evolving molecules using multi-objective optimization: applying to ADME***By Sean Ekins, J. Dana Honeycutt and James T. Metz***Spinal cord injury in vitro: modelling axon growth inhibition***By Mohammad Abu-Rub, Siobhan McMahon, Dimitrios I. Zeugolis, Anthony Windebank and Abhay Pandit*